DEMANT: Raised Fair Value And EU AI Rules May Shape Re Rating

Analysts have lifted the fair value estimate for Demant from DKK 229.83 to DKK 240.32. This reflects updated targets from firms such as Deutsche Bank and Morgan Stanley and is supported by assumptions for slightly higher revenue growth, improved profit margins, and a modestly lower discount rate, while keeping future P/E expectations broadly unchanged.

Analyst Commentary

Bullish Takeaways

Bullish analysts have raised their price targets into the DKK 220s, which aligns with the higher fair value estimate and signals confidence that current execution can support this valuation range.
The upward adjustments suggest comfort with the company’s ability to sustain its current profit profile, which supports the use of a slightly lower discount rate in valuation models.
Recent upgrades point to a view that the stock’s risk or execution concerns have eased somewhat, making the existing P/E assumptions look more reasonable relative to perceived growth potential.
Target revisions indicate that bullish analysts see room for the company to keep delivering on revenue and margin assumptions without requiring a major re-rating of the P/E multiple.

Bearish Takeaways

Some analysts still sit on Hold ratings even after raising targets, which indicates they see the current share price as broadly in line with their valuation work, not a clear bargain.
The reliance on a modestly lower discount rate means part of the higher fair value is tied to valuation inputs rather than new evidence on underlying business performance.
With future P/E expectations described as broadly unchanged, more cautious analysts appear unconvinced that there is enough visibility on earnings to justify a higher multiple.
Incremental target moves suggest that while the outlook has improved at the margin, there is still some hesitation around how consistently the company can deliver against the growth and margin assumptions baked into current fair value estimates.

What's in the News

Demant CEO Søren Nielsen has raised concerns that new EU AI regulations could create parallel regulatory tracks for medical devices, adding extra bureaucracy for companies that use AI in their products. (Source: recent news report, 22 May 2026)
Industry associations referenced by Nielsen highlight the risk that separate AI rules and medical device rules could extend approval timelines for new AI based medical products. (Source: recent news report, 22 May 2026)
There is also a concern that some existing AI based medical devices might need to be withdrawn from the European market if they cannot meet overlapping regulatory requirements. (Source: recent news report, 22 May 2026)
Nielsen and sector groups are calling for EU policymakers to revise Medical Device Regulations so that AI device oversight sits within a single, integrated framework instead of split regimes. (Source: recent news report, 22 May 2026)

Valuation Changes

Fair Value: DKK 229.83 to DKK 240.32, a small uplift in the modelled valuation range.
Discount Rate: 7.08% to 6.41%, a moderate reduction that increases the present value of future cash flows in the model.
Revenue Growth: 7.98% to 8.36%, a slight increase in assumed DKK revenue growth expectations.
Net Profit Margin: 11.89% to 12.09%, a modest upward adjustment in expected profitability.
Future P/E: 17.07x to 17.05x, essentially unchanged, indicating similar expectations for the earnings multiple applied to the stock.

1 view

Key Takeaways

Rising hearing health awareness and reduced stigma, combined with demographic trends, are expected to boost long-term demand and support recovery in revenues.
Investment in advanced products and retail expansion positions Demant for premium market share, scalable service revenues, and enhanced profitability as conditions improve.
Macroeconomic uncertainty, shifting geographic mix, and increased competition are reducing margins and profitability, while persistent volatility challenges long-term growth and earnings stability.

Catalysts

About Demant

Operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally.What are the underlying business or industry changes driving this perspective?

Current market uncertainty and consumer hesitancy, especially among first-time users, are leading to postponed purchases and upgrades, suppressing near-term revenue growth; as global economic conditions and consumer confidence normalize, underlying demographic demand from an aging population is expected to return, providing a tailwind for top-line growth and recurring revenue recovery.
Increased public focus on hearing health, combined with initiatives to reduce stigma around hearing aids and greater awareness of long-term negative consequences of untreated hearing loss, suggest that penetration rates could rise, supporting volume growth and eventually higher revenues as macro headwinds diminish.
Continued heavy investment in R&D and ongoing commitment to launching two major product updates annually (with a robust pipeline), including advancements in AI-enabled and connected hearing devices, position Demant to capture premium share with differentiated features, positively impacting future net margins and maintaining pricing power as digital adoption accelerates.
Expansion of the hearing care retail and clinic network (including the KIND Group acquisition) increases access to care in strategically important geographies, paving the way for cross-selling of services and devices, growing high-margin recurring service revenues and improving long-term earnings stability and scalability.
Operational discipline with tightened cost control during periods of weak market growth, alongside plans for efficiency gains and scale benefits from integration, positions Demant to expand margins as volumes recover-enabling a more leveraged return to profit growth once secular demand trends reassert themselves.

Demant Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Demant's revenue will grow by 8.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 10.3% today to 12.1% in 3 years time.
Analysts expect earnings to reach DKK 3.5 billion (and earnings per share of DKK 17.2) by about June 2029, up from DKK 2.4 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as DKK4.0 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.1x on those 2029 earnings, down from 22.5x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 29.5x.
Analysts expect the number of shares outstanding to decline by 0.31% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.41%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent macroeconomic uncertainty and consumer cautiousness have led to lower-than-expected market growth, causing both delays in new purchases and upgrades of hearing aids-this reduces overall demand and impacts revenue and profitability.
Shift in sales toward lower ASP (average selling price) geographies and product mixes (e.g., growth mainly outside the US and in free-to-client categories in key markets like France) has led to declining global ASP and unfavorable geographic mix; this erodes group gross margins and reduces EBIT.
Intensifying competition-especially as more suppliers split large retailer contracts (e.g., cost channel dynamics with Sonova's return)-creates ongoing risk of lost market share and necessitates higher operational and promotional spending, further impacting net margins.
Diagnostic business remains challenged by postponed investments, particularly in the US, due to ongoing economic uncertainty and tight government budgets, which could lead to prolonged revenue stagnation in this segment.
Heightened market volatility and lack of consistent secular growth make long-term planning difficult and increase the risk that Demant's current margin pressures (from operational leverage, geographic mix, and market dynamics) could persist or worsen, constraining earnings growth over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of DKK240.32 for Demant based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK275.0, and the most bearish reporting a price target of just DKK170.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be DKK29.2 billion, earnings will come to DKK3.5 billion, and it would be trading on a PE ratio of 17.1x, assuming you use a discount rate of 6.4%.
Given the current share price of DKK252.2, the analyst price target of DKK240.32 is 4.9% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Demant?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DEMANT: Rising Share Buybacks Will Drive Medium-Term Upside Momentum